Kevin J Harrington

INDUCE-3: A Gerandomiseerde Fase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent...

Clinical cancer research : an official journal of the American Association for Cancer Research · 16 maart 2026

Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ...

The Lancet. Oncology · 2025-09

Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, ...

The Lancet. Oncology · 2025-09

Fase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with G...

Clinical cancer research : an official journal of the American Association for Cancer Research · 14 augustus 2025

Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies.

European journal of cancer (Oxford, England : 1990) · 25 juli 2025

Neoadjuvant and Adjuvant Pembrolizumab in Locally Gevorderd Head and Neck Cancer.

The New England journal of medicine · 3 juli 2025

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year f...

European journal of cancer (Oxford, England : 1990) · 15 mei 2025

Pembrolizumab plus CRT versus placebo plus CRT bij hoofd-halscarcinoom: KEYNOTE-412 fase III

The Lancet. Oncology · 2024-05

Pembrolizumab met of zonder chemotherapie bij recidief hoofd-halscarcinoom: KEYNOTE-048 driejaars

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 februari 2023

Dosisgeëscaleerde IMRT bij lokaal gevorderd larynx-/hypofarynxcarcinoom

European journal of cancer (Oxford, England : 1990) · 2021-08

Patritumab plus cetuximab-platina bij recidief hoofd-halscarcinoom: fase II

European journal of cancer (Oxford, England : 1990) · 2019-12

Pembrolizumab alleen of met chemotherapie versus cetuximab-chemotherapie bij recidief hoofd-halscarcinoom: KEYNOTE-048 fase III

Lancet (London, England) · 23 november 2019

Nivolumab bij recidief hoofd-halsplaveiselcelcarcinoom: langetermijn effectiviteitsdata

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 september 2019

Pembrolizumab versus methotrexaat/docetaxel/cetuximab bij recidief hoofd-halscarcinoom: KEYNOTE-040 fase III

Lancet (London, England) · 12 januari 2019

Nivolumab versus standaard monotherapie bij recidief hoofd-halsplaveiselcelcarcinoom: geactualiseerde CheckMate 141 analyse

The Lancet. Oncology · 2017-08